A Phase 3 interventional study of NVX-Cov2373 in COVID-19 and SARS-CoV-2 Infection, sponsored by Novavax. Completed at 30 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Novavax · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.
Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 11th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 9th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9 · Phase 4 5
First in 2020; this study’s year is marked. 5 started in 2022.
This study's enrollment of 911 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 997 across the 18 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 7 most frequent:
Novavax is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
21 studies in COVID-19 by Novavax: none open now, none under way, none of them phase 3. Of 18 finished, 4 (22%) have results posted.
Among the 21 studies in COVID-19 by Novavax, this one is the 11th largest by enrollment, is one of 6 that started in 2022, is one of 8 in phase 3, and was the 9th registered.
Novavax’s COVID-19 studies by the year they started, since 2020.
1 of the studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07861542SanofiStudy of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 | 2026-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, from their registry updates:
Among Novavax’s 21 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373). The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive. Participants will be screened at baseline with the goal of enrolling approximately 900 previously vaccinated participants. Participants will be randomized 1:1:1 to receive 1 dose of the vaccine from 1 of 3 different lots, given on Day 1, at a dose level of 5 µg of antigen with 50 µg of Matrix-M adjuvant. All participants will remain on study for immunogenicity and safety data collection through 28 days following the vaccination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be included in this study, each individual must satisfy all of the following criteria:
Agree to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study.
Note: For participants who become hospitalized with coronavirus disease 2019 (COVID-19), participation in treatment studies is permitted.
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
Drug: NVX-Cov2373
1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
Drug: NVX-Cov2373
1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
Drug: NVX-Cov2373
Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
Also known as: SARS-CoV-2 rS/Matrix-M Adjuvant
Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs]
Serum Immunoglobulin G (IgG) geometric mean ELISA unit concentrations (GMEU/mL) to the SARS-CoV-2 spike protein at Day 29 in each treatment arm.
Time frame: Baseline (Day 1) and Day 29
Serum IgG Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Seroconversion Rate (SCR)
Proportion of participants in each treatment arm who achieve seroconversion (≥ 4-fold increase from baseline) in IgG concentrations to the SARS-CoV-2 spike protein at Day 29.
Time frame: Day 29
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as Geometric Mean Titer [GMT]
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 1 and Day 29
Time frame: Baseline (Day 1) to Day 29
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as SCR
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 29
Time frame: Day 29
hACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as GMT
hACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 1 to Day 29
Time frame: Baseline (Day 1) to Day 29
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 29
Time frame: Day 29
Number of Participants With Medically Attended Adverse Event(s) (MAAEs), Adverse Event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)
Number of participants Medically Attended Adverse Event(s) (MAAEs), Adverse event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)
Time frame: Day 1 to Day 29
Incidence and Severity of MAAEs Through Day 29
Incidence, duration, severity, and relationship of MAAEs through Day 29 (ie, 28 days after vaccine dose)
Time frame: Day 29
Number of Participants With Unsolicited Treatment-Emergent Adverse Events by COVID-19
Number of Participants with Unsolicited Treatment-Emergent Adverse Events by COVID-19 throughout the study at Day 29
Time frame: Day 29
| Milestone | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Started | 298 | 303 | 304 |
| Completed | 283 | 289 | 293 |
| Not completed | 15 | 14 | 11 |
| Withdrew: Lost to follow-up | 4 | 2 | 5 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 |
| Withdrew: Sponsor decision | 6 | 9 | 3 |
| Withdrew: Others | 1 | 1 | 1 |
Serum Immunoglobulin G (IgG) geometric mean ELISA unit concentrations (GMEU/mL) to the SARS-CoV-2 spike protein at Day 29 in each treatment arm.
| Elisa Units per mL | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Baseline (Day 1) | 34294.3 (29549.6 to 39800.9) | 36142.6 (31430.8 to 41560.8) | 33233.4 (28863.0 to 38265.4) |
| Day 29 | 91945.8 (82821.7 to 102075.0) | 93084.2 (84250.8 to 102843.7) | 88811.3 (86164.5 to 96589.6) |
Proportion of participants in each treatment arm who achieve seroconversion (≥ 4-fold increase from baseline) in IgG concentrations to the SARS-CoV-2 spike protein at Day 29.
| Percentage of participants | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Serum IgG Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Seroconversion Rate (SCR) | 23.0 (18.2 to 28.5) | 21.2 (16.5 to 26.5) | 25.4 (20.4 to 30.8) |
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 1 and Day 29
| geometric mean titers | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Baseline (Day 1) | 1211.0 (1028.9 to 1425.2) | 1289.4 (1114.2 to 1492.3) | 1103.7 (950.1 to 1282.1) |
| Day 29 | 2838.7 (2532.6 to 3181.8) | 2823.5 (2529.0 to 3152.4) | 2603.2 (2341.2 to 2894.6) |
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 29
| Percentage of participants | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as SCR | 32.4 (26.9 to 38.2) | 32.9 (27.4 to 38.7) | 35.9 (30.3 to 41.7) |
hACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 1 to Day 29
| geometric mean titers | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Baseline (Day 1) | 142.3 (121.6 to 166.6) | 142.3 (127.0 to 170.5) | 128.8 (110.9 to 149.5) |
| Day 29 | 332.1 (299.1 to 368.7) | 329.1 (296.9 to 364.8) | 319.1 (289.9 to 351.2) |
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 29
| Percentage of participants | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR | 20.4 (15.8 to 25.8) | 18.6 (14.2 to 23.7) | 23.2 (18.5 to 28.6) |
Number of participants Medically Attended Adverse Event(s) (MAAEs), Adverse event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)
| Participants | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Serious AEs | 0 | 1 | 1 |
| MAAEs | 15 | 12 | 12 |
| AESIs | 0 | 0 | 0 |
Incidence, duration, severity, and relationship of MAAEs through Day 29 (ie, 28 days after vaccine dose)
| Participants | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| MAAEs | 15 | 12 | 12 |
| Related MAAEs | 2 | 2 | 2 |
Number of Participants with Unsolicited Treatment-Emergent Adverse Events by COVID-19 throughout the study at Day 29
| Participants | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Unsolicited TEAEs | 15 | 12 | 12 |
| Related TEAEs | 2 | 2 | 2 |
Collected over 29 Days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lot 1 | 0/298 (0%) | 0/298 (0%) | 7/298 (2.3%) |
| Lot 2 | 0/303 (0%) | 1/303 (0.3%) | 3/303 (1%) |
| Lot 3 | 0/304 (0%) | 1/304 (0.3%) | 4/304 (1.3%) |
| Event | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/298 | 1/303 | 0/304 |
| Escherichia infectionInfections and infestations | 0/298 | 0/303 | 1/304 |
| Event | Lot 1 | Lot 2 | Lot 3 |
|---|---|---|---|
| COVID-19Infections and infestations | 7/298 | 3/303 | 4/304 |
Safety Analysis Set
| Age, Continuous(years) | Lot 1 | Lot 2 | Lot 3 | Total |
|---|---|---|---|---|
| Mean | 36.2 ± 8.31 | 36.5 ± 8.80 | 36.6 ± 8.06 | 36.4 ± 8.39 |
| Sex: Female, Male(Participants) | Lot 1 | Lot 2 | Lot 3 | Total |
|---|---|---|---|---|
| Female | 175 | 165 | 186 | 526 |
| Male | 123 | 138 | 118 | 379 |
| Ethnicity (NIH/OMB)(Participants) | Lot 1 | Lot 2 | Lot 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 50 | 41 | 52 | 143 |
| Not Hispanic or Latino | 245 | 259 | 248 | 752 |
| Unknown or Not Reported | 3 | 3 | 4 | 10 |
| Race/Ethnicity, Customized(Participants) | Lot 1 | Lot 2 | Lot 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 3 | 7 |
| Asian | 11 | 10 | 9 | 30 |
| Black or African American | 54 | 61 | 51 | 166 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 3 | 3 |
| White or Caucasian | 219 | 223 | 228 | 670 |
| Other | 8 | 3 | 9 | 20 |
| Not reported/specified | 3 | 5 | 1 | 9 |
| Previous SARS-CoV-2 infection, n (%)(Participants) | Lot 1 | Lot 2 | Lot 3 | Total |
|---|---|---|---|---|
| Count of participants | 17 | 13 | 14 | 44 |
| PCR, n (%)(Participants) | Lot 1 | Lot 2 | Lot 3 | Total |
|---|---|---|---|---|
| Positive | 7 | 8 | 6 | 21 |
| Negative | 282 | 288 | 289 | 859 |
| Missing | 9 | 7 | 9 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2022 to primary completion in Aug 2022, 1 month.
Results were first posted in Apr 2026, 3 years 8 months after primary completion. A results delay was requested in Mar 2023.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle